JAK inhibitors have not been able to eradicate neoplastic clones, as seen in targeted therapy with tyrosine kinase inhibitor (TKI) treatment for BCR::ABL1-positive chronic myeloid leukemia (CML). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.